Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 39

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 39
---
, a wholly-owned potential best-in-class amyloid depleter antibody for the treatment of AL amyloidosis designed to directly neutralize soluble toxic light chain aggregates and promote clearance of amyloid that causes organ dysfunction and failure. In 2024, Prothena published Birtamimab’s mechanism of action and pharmacological characteristics in Leukemia & Lymphoma and presented Longitudinal Health-Related Quality of Life data (SF-36v2) across

| 2025 PROXY STATEMENT |     | 23 |

TABLE OF CONTENTS

#### PROPOSAL NO. 3 – “SAY-ON-PAY”
domains from the VITAL Phase 3 clinical trial at the International Society of Amyloidosis. We continued the confirmatory Phase 3 AFFIRM-AL clinical trial (NCT04973137) in patients with Mayo Stage IV AL amyloidosis under a Special Protocol Assessment (SPA) agreement with the FDA with a primary endpoint of all cause mortality (time-to-event) at a significance level of 0.10.

◦ Coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for the treatment of ATTR cardiomyopathy designed to deplete the pathogenic, non-native forms of the transthyretin (TTR) protein and is being developed by Novo Nordisk as part of their up to $1.2 billion acquisition of our ATTR amyloidosis business and pipeline. In 2024, Phase 1 clinical trial results for coramitug in patients with ATTR amyloidosis was published in Amyloid, the official

journal of the International Society of Amyloidosis, and Novo Nordisk continued the ongoing Phase 2 signal-detection clinical trial in patients with ATTR-CM.

• We Carefully Managed our Cash Balance .

◦ During fiscal year 2024, we carefully managed our capital. While progressing all of our development programs described above, our cash used in operating and investing activities was $150.3 million, which was in-line with our guidance range of $148 to $160 million. We finished fiscal year 2024 with $472.2 million in cash, cash equivalents, and restricted cash, including cash used in operating and financing activities, which exceeded our guidance of $468.0 million, providing a solid financial foundation for continuing to advance the Company’s discovery and clinical programs.

| Recommendation of the Board |

Our Board believes that the information provided above and in the Compensation Discussion and